Stock Events

Stock Events

Merrimack Pharmaceuticals 

$15.13
18
+$0+0% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Dec 19
$0.5
Sep 19
$1.5
May 17
$10.55
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

15MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.03
-0.03
-0.02
-0.02
Expected EPS
N/A
Actual EPS
-0.03

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
0Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MACK. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a leading biopharmaceutical company focusing on cancer, a direct competition to Merrimack's oncology focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. specializes in cancer treatments and vaccines, directly competing in the oncology space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio including oncology, directly competing with Merrimack's cancer therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. focuses on antiviral drugs and cancer treatments, making it a competitor in the oncology market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotech firm with a strong emphasis on cancer and serious illness treatments, competing in the same space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a diverse biopharmaceutical portfolio including oncology, directly competing with Merrimack.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in oncology, among other areas, competing with Merrimack.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on a wide range of healthcare areas including oncology, making it a direct competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong focus on oncology, respiratory diseases, and more, competing in the cancer treatment space.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the oncology market, among other healthcare sectors.

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Country
US
ISIN
US5903282094

Listings

0 Comments

Share your thoughts

FAQ

What is Merrimack Pharmaceuticals stock price today?▼
The current price of MACK is $15.13 USD — it has increased by +0% in the past 24 hours. Watch Merrimack Pharmaceuticals stock price performance more closely on the chart.
What is Merrimack Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Merrimack Pharmaceuticals stocks are traded under the ticker MACK.
What were Merrimack Pharmaceuticals earnings last quarter?▼
MACK earnings for the last quarter are -0.03 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Merrimack Pharmaceuticals revenue for the last year?▼
Merrimack Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Merrimack Pharmaceuticals net income for the last year?▼
MACK net income for the last year is 0 USD.
Does Merrimack Pharmaceuticals pay dividends?▼
Yes, MACK dividends are paid annual. The last dividend per share was 0.5 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Merrimack Pharmaceuticals located?▼
Merrimack Pharmaceuticals operates in the Professional, Scientific, and Technical Services sector.
When did Merrimack Pharmaceuticals complete a stock split?▼
The last stock split for Merrimack Pharmaceuticals was on September 06, 2017 with a ratio of 1:10.